HRP20240162T1 - Kristalna sol epinefrin malonata - Google Patents
Kristalna sol epinefrin malonata Download PDFInfo
- Publication number
- HRP20240162T1 HRP20240162T1 HRP20240162TT HRP20240162T HRP20240162T1 HR P20240162 T1 HRP20240162 T1 HR P20240162T1 HR P20240162T T HRP20240162T T HR P20240162TT HR P20240162 T HRP20240162 T HR P20240162T HR P20240162 T1 HRP20240162 T1 HR P20240162T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- epinephrine
- preparation according
- epinephrine malonate
- butanol
- Prior art date
Links
- 229930182837 (R)-adrenaline Natural products 0.000 title claims 16
- 229960005139 epinephrine Drugs 0.000 title claims 16
- -1 epinephrine malonate salt Chemical class 0.000 title claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 10
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 4
- 206010027654 Allergic conditions Diseases 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- IWTBVKIGCDZRPL-LURJTMIESA-N 3-Methylbutanol Natural products CC[C@H](C)CCO IWTBVKIGCDZRPL-LURJTMIESA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000007936 buccal or sublingual tablet Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims 1
- 229960004592 isopropanol Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Claims (26)
1. Sol epinefrin malonata u kristalnom obliku.
2. Sol epinefrin malonata prema patentnom zahtjevu 1, naznačena time što kristalni oblik ima spektar rendgenske difrakcije praha koji ima jedan ili više pikova izraženih kao 2 teta na otprilike 12.1843, 13.4653, 14.2595, 14.6991, 15.8664, 17.3570, 17.9004, 19.5883, 20.4659, 21.5801, 22.3908, 22.9301, 23.8776, 24.6585, 25.3418, 26.0105, 26.4829, 25.3418, 26.0105, 26.4829, 27.2385, 27.8939, 29.4741, 33.2425, 34.2629, 34.8439.
3. Farmaceutski pripravak koji sadrži sol epinefrin malonata i farmaceutski prihvatljiv nosač.
4. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time što je farmaceutski pripravak pogodan za oralnu, rektalnu, intraželučanu, topikalnu, intrakranijalnu, intranazalnu i parenteralnu primjenu.
5. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time što je farmaceutski pripravak pogodan za sublingvalnu ili bukalnu primjenu.
6. Farmaceutski pripravak prema patentnom zahtjevu 5, naznačen time što farmaceutski pripravak sadrži punilo i sredstvo za raspadanje.
7. Farmaceutski pripravak prema patentnom zahtjevu 6, naznačen time što punilo je mikrokristalna celuloza i sredstvo za raspadanje je unakrsno vezani polivinil polipirolidon.
8. Farmaceutski pripravak prema patentnom zahtjevu 7, naznačen time što je punilo prisutno u količini od 20 do 30 težinskih % i sredstvo za raspadanje je prisutno u količini od 5 do 15 težinskih %.
9. Farmaceutski pripravak prema patentnom zahtjevu 8, koji dodatno sadrži lubrikant i klizajuće sredstvo.
10. Farmaceutski pripravak prema patentnom zahtjevu 9, naznačen time što je lubrikant magnezij stearat i klizajuće sredstvo je silicij dioksid.
11. Farmaceutski pripravak prema patentnom zahtjevu 10, koji dodatno sadrži razrjeđivač.
12. Farmaceutski pripravak prema patentnom zahtjevu 11, naznačen time što razrjeđivač je manitol.
13. Farmaceutski pripravak prema patentnom zahtjevu 12, koji dodatno sadrži limunsku kiselinu.
14. Farmaceutski pripravak prema patentnom zahtjevu 5, naznačen time što pripravak sadrži količinu od 0.3 do 10 mg slobodne baze epinefrina.
15. Farmaceutski pripravak prema patentnom zahtjevu 5, naznačen time što se farmaceutski pripravak raspada za manje od ili jednako 30 sekundi.
16. Postupak za proizvodnju soli epinefrin malonata, naznačen time što navedeni postupak sadrži:
dodavanje malonske kiseline u otopinu koja sadrži epinefrin i rastvarač;
miješanje otopine; i
taloženje soli epinefrin malonata iz otopine.
17. Postupak prema patentnom zahtjevu 16, koji dodatno sadrži talog.
18. Postupak prema patentnom zahtjevu 17, koji dodatno sadrži sušenje taloga.
19. Postupak prema patentnom zahtjevu 16, naznačen time što se malonska kiselina dodaje u odnosu od 0.01:1 do 3:1 u odnosu na epinefrin.
20. Postupak prema patentnom zahtjevu 16, naznačen time što je otapalo izabrano iz grupe koja se sastoji od metanola, etanola, n-propanola, izo-propanola, n-butanola, sek-butanola, terc-butanola, n-pentanola, 2-metil-butanola, 3-metil-butanola i heksanola.
21. Postupak prema patentnom zahtjevu 20, naznačen time što otapalo je etanol.
22. Epinefrin malonat za uporabu u liječenju alergijskog stanja.
23. Epinefrin malonat za uporabu prema patentnom zahtjevu 22, naznačen time što se epinefrin malonat primjenjuje oralno, rektalno, intraželučano, topikalno, intrakranijalno, intranazalno ili parenteralno.
24. Epinefrin malonat za uporabu prema patentnom zahtjevu 22, naznačen time što se epinefrin malonat primjenjuje putem bukalne ili sublingvalne tablete.
25. Epinefrin malonat za uporabu prema patentnom zahtjevu 22, naznačen time što je alergijsko stanje izabrano iz grupe koja se sastoji od anafilakse, astme ili bronhijalne astme.
26. Epinefrin malonat za uporabu prema patentnom zahtjevu 25, naznačen time što alergijsko stanje je anafilaksa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711936P | 2018-07-30 | 2018-07-30 | |
| US201862731442P | 2018-09-14 | 2018-09-14 | |
| EP19845343.3A EP3829551B1 (en) | 2018-07-30 | 2019-07-29 | Crystalline epinephrine malonate salt |
| PCT/US2019/043856 WO2020028215A1 (en) | 2018-07-30 | 2019-07-29 | Crystalline epinephrine malonate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240162T1 true HRP20240162T1 (hr) | 2024-04-12 |
Family
ID=69179001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240162TT HRP20240162T1 (hr) | 2018-07-30 | 2019-07-29 | Kristalna sol epinefrin malonata |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10995059B2 (hr) |
| EP (1) | EP3829551B1 (hr) |
| JP (1) | JP2021532161A (hr) |
| KR (1) | KR20210057022A (hr) |
| CN (1) | CN112739334A (hr) |
| AU (1) | AU2019313324A1 (hr) |
| BR (1) | BR112021001525A2 (hr) |
| CA (1) | CA3123928C (hr) |
| HR (1) | HRP20240162T1 (hr) |
| IL (1) | IL280448A (hr) |
| MX (1) | MX2021001249A (hr) |
| PL (1) | PL3829551T3 (hr) |
| RS (1) | RS65138B1 (hr) |
| SG (1) | SG11202100749UA (hr) |
| TW (1) | TWI819045B (hr) |
| WO (1) | WO2020028215A1 (hr) |
| ZA (2) | ZA202100765B (hr) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2332075A (en) | 1940-05-24 | 1943-10-19 | Wilson & Co Inc | Epinephrine derivative and preparation thereof |
| US2469967A (en) | 1946-04-17 | 1949-05-10 | Armour & Co | Cyclopentano perhydrophenanthrene compounds |
| US2602818A (en) * | 1949-07-25 | 1952-07-08 | Parke Davis & Co | Process for the purification of epinephrine |
| CN1406126A (zh) * | 1998-10-01 | 2003-03-26 | 诺瓦提斯公司 | 新型缓释口服制剂 |
| LT1531794T (lt) * | 2002-06-28 | 2017-08-25 | Civitas Therapeutics, Inc. | Inhaliuojamas epinefrinas |
| TW200800142A (en) | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| WO2009004593A2 (en) * | 2007-07-03 | 2009-01-08 | Wockhardt Research Centre | Processes for the preparation of epinephrine |
| WO2015054359A1 (en) * | 2013-10-08 | 2015-04-16 | Ebadi Mark A | Methods and compositions for symptomatic reflief of the common cold |
| US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
| BR112018013979A2 (pt) * | 2016-01-07 | 2018-12-11 | Viramal Ltd | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos |
-
2019
- 2019-07-29 CN CN201980050690.2A patent/CN112739334A/zh active Pending
- 2019-07-29 HR HRP20240162TT patent/HRP20240162T1/hr unknown
- 2019-07-29 JP JP2021505650A patent/JP2021532161A/ja active Pending
- 2019-07-29 RS RS20240136A patent/RS65138B1/sr unknown
- 2019-07-29 CA CA3123928A patent/CA3123928C/en active Active
- 2019-07-29 MX MX2021001249A patent/MX2021001249A/es unknown
- 2019-07-29 WO PCT/US2019/043856 patent/WO2020028215A1/en active Application Filing
- 2019-07-29 KR KR1020217006214A patent/KR20210057022A/ko unknown
- 2019-07-29 PL PL19845343.3T patent/PL3829551T3/pl unknown
- 2019-07-29 AU AU2019313324A patent/AU2019313324A1/en active Pending
- 2019-07-29 SG SG11202100749UA patent/SG11202100749UA/en unknown
- 2019-07-29 EP EP19845343.3A patent/EP3829551B1/en active Active
- 2019-07-29 BR BR112021001525-6A patent/BR112021001525A2/pt unknown
- 2019-07-30 US US16/526,286 patent/US10995059B2/en active Active
- 2019-07-30 TW TW108127025A patent/TWI819045B/zh active
-
2021
- 2021-01-27 IL IL280448A patent/IL280448A/en unknown
- 2021-02-03 ZA ZA2021/00765A patent/ZA202100765B/en unknown
- 2021-03-29 US US17/216,003 patent/US11505521B2/en active Active
-
2022
- 2022-01-26 ZA ZA2022/01224A patent/ZA202201224B/en unknown
- 2022-11-18 US US17/989,859 patent/US20230086578A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123928A1 (en) | 2020-02-06 |
| ZA202201224B (en) | 2023-11-29 |
| US20230086578A1 (en) | 2023-03-23 |
| US11505521B2 (en) | 2022-11-22 |
| CA3123928C (en) | 2023-11-14 |
| PL3829551T3 (pl) | 2024-04-02 |
| EP3829551A1 (en) | 2021-06-09 |
| CN112739334A (zh) | 2021-04-30 |
| EP3829551C0 (en) | 2024-01-03 |
| ZA202100765B (en) | 2022-08-31 |
| KR20210057022A (ko) | 2021-05-20 |
| IL280448A (en) | 2021-03-25 |
| TW202010491A (zh) | 2020-03-16 |
| AU2019313324A1 (en) | 2021-02-04 |
| JP2021532161A (ja) | 2021-11-25 |
| RS65138B1 (sr) | 2024-02-29 |
| US10995059B2 (en) | 2021-05-04 |
| EP3829551A4 (en) | 2022-04-20 |
| BR112021001525A2 (pt) | 2021-04-20 |
| US20200031758A1 (en) | 2020-01-30 |
| SG11202100749UA (en) | 2021-02-25 |
| US20210214301A1 (en) | 2021-07-15 |
| EP3829551B1 (en) | 2024-01-03 |
| MX2021001249A (es) | 2021-05-27 |
| WO2020028215A1 (en) | 2020-02-06 |
| TWI819045B (zh) | 2023-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516883A5 (hr) | ||
| JP2018035160A5 (hr) | ||
| PE20231301A1 (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este | |
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| JP2015514060A5 (hr) | ||
| JP2015518885A5 (hr) | ||
| CA2713292A1 (en) | Delayed release rasagiline formulation | |
| JP2009513604A5 (hr) | ||
| JP2007533687A5 (hr) | ||
| DE22154751T1 (de) | Tetrahydrobiopterin zur behandlung von zuständen, welche mit erhöhten phenylalanin-spiegeln einhergehen | |
| MXPA03006974A (es) | Indanil aminas aciladas y su uso como farmacos. | |
| JP2009541334A5 (hr) | ||
| CA2777824A1 (en) | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | |
| JP2009534312A5 (hr) | ||
| WO2002066480A3 (en) | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders | |
| JP2007532560A5 (hr) | ||
| JP2014511374A5 (hr) | ||
| JP2019509268A5 (hr) | ||
| JP2014198723A5 (hr) | ||
| JP2018529742A5 (hr) | ||
| JP2010514807A5 (hr) | ||
| WO2017021921A1 (en) | Process for the preparation of pharmaceutical grade ferric citrate | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| PH12020551488A1 (en) | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
| JP2021073257A5 (hr) |